HOPE Cardiometabolic Research Team & Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria.
Department of Physiology, College of Medicine and Health Sciences, Afe Babalola University, Ado-Ekiti, Nigeria.
J Endocrinol. 2020 Jul;246(1):1-12. doi: 10.1530/JOE-19-0582.
Adipose dysfunction and inflammation with or without hepatic defects underlie metabolic obesity. Glutamine (GLU) improves glucoregulation and metabolic indices but its effects on adipose function and hepatic lipid deposition in estrogen-progestin oral contraceptive (EPOC) users are unknown. Therefore, we hypothesized that GLUT supplementation would protect against adipose dysfunction and excess hepatic lipid influx and deposition in EPOC-treated animals by suppressing adenosine deaminase/xanthine oxidase (ADA/XO) activity and improving glucose-6-phosphate dehydrogenase (G6PD)-dependent antioxidant defense. Female Wistar rats weighing 150-180 g were allotted into control, GLUT, EPOC and EPOC + GLUT groups (six rats/group). The groups received vehicle (distilled water, p.o.), GLUT (1 g/kg), EPOC containing 1.0 µg ethinylestradiol plus 5.0 µg levonorgestrel and EPOC plus GLUT, respectively, daily for 8 weeks. Results showed that the administration of EPOC caused glucose dysregulation and increased triglyceride-glucose index and visceral adiposity, but the body weight and liver weight were not affected. However, EPOC significantly decreased adipose lipid, G6PD and glutathione and increased glycogen synthesis, ADA, XO, uric acid, lipid peroxidation, lactate production and gamma-glutamyl transferase activity (GGT). On the other hand, EPOC increased hepatic lipid, ADA, XO, uric acid, lipid peroxidation and lactate production and decreased glycogen synthesis, G6PD and glutathione. Nevertheless, supplementation with glutamine attenuated these alterations. Collectively, the present results indicate that EPOC causes metabolically induced obesity which is associated with adipose dysfunction and hepatic metabolic disturbance. The findings also suggest that glutamine confers metabo-protection with corresponding improvement in adipose and hepatic metabolic function by suppression of ADA/XO activity and enhancement of G6PD-dependent antioxidant defense.
脂肪功能障碍和炎症,无论是否伴有肝缺陷,都是代谢性肥胖的基础。谷氨酰胺(GLU)可改善糖调节和代谢指标,但它对雌激素-孕激素口服避孕药(EPOC)使用者脂肪功能和肝脂质沉积的影响尚不清楚。因此,我们假设 GLUT 补充剂通过抑制腺苷脱氨酶/黄嘌呤氧化酶(ADA/XO)活性和改善葡萄糖-6-磷酸脱氢酶(G6PD)依赖性抗氧化防御,可防止脂肪功能障碍和 EPOC 处理动物中过多的肝脂质流入和沉积。体重 150-180 g 的雌性 Wistar 大鼠分为对照组、GLUT 组、EPOC 组和 EPOC+GLUT 组(每组 6 只)。各组分别给予载体(蒸馏水,po)、GLUT(1 g/kg)、含 1.0 µg 乙炔雌二醇和 5.0 µg 左炔诺孕酮的 EPOC 和 EPOC+GLUT,每日一次,共 8 周。结果表明,EPOC 的给予导致葡萄糖调节异常,增加甘油三酯-葡萄糖指数和内脏肥胖,但体重和肝重不受影响。然而,EPOC 显著降低脂肪脂质、G6PD 和谷胱甘肽,增加糖原合成、ADA、XO、尿酸、脂质过氧化、乳酸生成和γ-谷氨酰转移酶活性(GGT)。另一方面,EPOC 增加肝脂质、ADA、XO、尿酸、脂质过氧化和乳酸生成,减少糖原合成、G6PD 和谷胱甘肽。然而,补充谷氨酰胺可减轻这些改变。总之,本研究结果表明,EPOC 导致代谢性诱导的肥胖,与脂肪功能障碍和肝代谢紊乱有关。研究结果还表明,谷氨酰胺通过抑制 ADA/XO 活性和增强 G6PD 依赖性抗氧化防御,提供代谢保护,并相应改善脂肪和肝代谢功能。